Page 6 - CUA KIDNEY CANCER HANDBOOK 2020
P. 6

Table of contents (con’t’d)


              Treatment Sequencing                                   45
              Considerations for Treatment Selection                 45
              Real-world Evidence (IMDC)                             45
              Drug Therapy                                           49

              Immunotherapy Agents                                   49
                 Avelumab (BAVENCIO )                                49
                               ®
                  Ipilimumab (YERVOY )                               51
                               ®
                              ®
                  Nivolumab (OPDIVO )                                53
                  Pembrolizumab (KEYTRUDA )                          56
                                    ®
              Anti-angiogenic Therapy (VEGF Receptor TKIs)           58
                  Axitinib (INLYTA )                                 58
                           ®
                  Cabozantinib (CABOMETYX )                          60
                                   TM
                               ®
                 Lenvatinib (LENVIMA )                               62
                                ®
                 Pazopanib (VOTRIENT )                               64
                 Sunitinib (SUTENT )                                 67
                             ®
              mTOR-targeted Agents                                   69
                 Everolimus (AFINITOR )                              69
                                ®
              Managing Toxicities                                    71
              Immune-related Adverse Events (IrAEs)                  71
                 General IrAE Management Principles                  71
                  Baseline Assessment                                71
                  Rash/Inflammatory Dermatitis IrAE                  72
                  Colitis IrAE                                       73
                 Pneumonitis IrAE                                    75
                  Hypothyroidism IrAE                                76
                  Inflammatory Arthritis IrAE                        77
                  Other IrAEs to Watch For                           78

              Resources                                              79
                 Prognostic Scoring – IMDC criteria                  79
                  ECOG Performance Status                            80
              Acronyms and Abbreviations                             81


              References                                             83











           4              Practical Approaches to Managing Advanced Kidney Cancer
   1   2   3   4   5   6   7   8   9   10   11